Skip to nav Skip to content

Clinical Trial Search

36 Clinical Trials Found

Clinical Trial 23203

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRCSD Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma
Disease Site: Multiple Myeloma
PI: Hansen, Doris

Clinical Trial 23536

A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA
Disease Site: Liver
PI: Kim, Richard

Clinical Trial 23586

Disease Site: Multiple Myeloma
PI: Hansen, Doris

Clinical Trial 23773

A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Disease Site: Brain and Nervous System, Kidney, Other Digestive Organ, Other Skin, Small Intestine, Stomach
PI: Blue, Brandon

Clinical Trial 21027

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Disease Site: Lung, Non small cell lung cancer
PI: Creelan, Benjamin

Clinical Trial 21113

A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered with a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients with Recurrent Ovarian Cancer
Disease Site: Ovary
PI: Wenham, Robert

Clinical Trial 22113

Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 23652

A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma
PI: Shah, Bijal

Clinical Trial 23082

Disease Site: Melanoma, skin
PI: Karapetyan, Lilit

Clinical Trial 21971

Phase I Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients with Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)
Disease Site: Lung
PI: Creelan, Benjamin

Clinical Trial 22080

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Locke, Frederick

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal